On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...
On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...
Zacks.com on MSN22h
NVO Q4 Earnings Beat Estimates, GLP-1 Drugs Boost Sales, Stock UpNovo Nordisk A/S NVO reported fourth-quarter 2024 earnings of 91 cents per American Depositary Receipt (ADR), which beat the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback